XBIT on Nasdaq

XBiotech Inc.

Canadian pharmaceutical preparations company, incorporated in British Columbia1

In its 2026 annual report the company says: “XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. The Company’s Internet address is www.xbiotech.com.”3 It is headquartered in Austin, Texas.1 Its shares trade on Nasdaq under the symbol XBIT.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with CervoMed Inc., Kala Pharmaceuticals (United States) or CHINA PHARMA HOLDINGS, INC., or pick any stock.

  • TickerXBIT on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAustin, Texas1
  • Incorporated inBritish Columbia, Canada2
  • Business address5217 Winnebago Lane, Austin, Tx 787442
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

XBiotech Inc. (“XBiotech” or the “Company”) is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. XBiotech was incorporated in Canada on March 22, 2005. The Company’s Internet address is www.xbiotech.com . The Company makes available free of charge on or through its website its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as proxy statements, as soon as reasonably practicable after the Company electronically files such material with, or furnishes it to, the Securities and Exchange Commission. The Company’s website is included in this annual report on Form 10-K as an inactive textual reference only. The information on, or accessible through…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 20234
-11.2%Return on equity5
-$19.1MFree cash flow6

Financial statements

Revenue784$0 in 2023
0$20.0M$40.0M$60.0M2019: $0$020192020: $44.0M$44.0M20202021: $18.4M$18.4M2021−58%2022: $4.0M$4.0M2022−78%2023: $0$02023
Gross profit784$0 in 2023
0$5.0M$10.0M$15.0M2019: $0$020192020: $9.4M$9.4M20202021: $12.6M$12.6M2021+33%2022: $3.4M$3.4M2022−73%2023: $0$02023
Operating income7846-$37.5M in 2023+20% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$31.2M-$31.2M20192020: -$18.3M-$18.3M2020−41%2021: -$25.1M-$25.1M2021+37%2022: -$34.5M-$34.5M2022+38%2023: -$37.5M-$37.5M2023+9%
Net income7846-$24.6M in 2023
-$200.0M0$200.0M$400.0M$600.0M$800.0M2019: $668.6M$668.6M20192020: -$11.2M-$11.2M20202021: -$17.4M-$17.4M2021+55%2022: -$32.9M-$32.9M2022+89%2023: -$24.6M-$24.6M2023−25%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development$47.4M$37.8M
General and administrative$8.3M$4.7M
Total operating expenses$42.5M
Loss from operations-$55.7M-$42.5M
Interest income$5.7M$9.8M
Interest expense-$88.0K-$807.0K
Other expense$1.5M$432.0K
Foreign exchange gain (loss)$3.3M-$5.5M
Total other income$10.4M$3.9M
Income before income taxes-$45.3M-$38.6M
Income tax (expense) benefit-$235.0K$32.0K
Net loss-$45.5M-$38.5M
Net loss per sharebasic and diluted (in dollars per share)-$1.49-$1.26
Shares used to compute basic and diluted net loss per share (in shares)30.5M shares30.5M shares

Compare XBiotech Inc. with another company

Corporate structure

XBiotech Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of XBiotech Inc.

  • John Simard Filed SCHEDULE 13G/A on XBiotech Inc., latest Jan 23, 2026 (5 filings since Feb 16, 2022)
  • W. Thorpe McKenzie Filed SCHEDULE 13G/A on XBiotech Inc., latest Jan 23, 2026 (5 filings since Feb 16, 2022)
  • Thomas Gut Filed SC 13G/A on XBiotech Inc., latest Feb 7, 2024 (3 filings since Jun 16, 2022)
  • Lombard International Assurance S.A. Filed SC 13G on XBiotech Inc., latest Jan 12, 2023 (2 filings since Jan 13, 2022)
  • XBiotech Inc. Austin, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What XBiotech Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$21.7M5 Dec 31, 2024$20.0M5 Dec 31, 2023+8.4%
Property and equipment, net$23.1M5 Dec 31, 2025$24.5M5 Dec 31, 2024−5.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$125.6M5 Dec 31, 2025$172.7M5 Dec 31, 2024−27.3%

Properties, in its own words

The Company owns 48 acres of industrial-zoned property located five miles from Austin’s central business district at the address of 5217 Winnebago Ln, Austin, TX, 78744. In 2016, the Company built a new combined R&D and manufacturing facility on this property. The Company uses this facility to conduct research, discover new product candidates, produce products for clinical studies and provide administrative space to support its drug development and other activities. In 2019, XBiotech constructed a new facility to house infectious disease and animal facilities. Located in a separate building on our campus, just a short walk from the Company’s main manufacturing headquarters, the new facility incorporates an animal biological safety level 2 (ABSL2) laboratory and other laboratories for developing and testing Company’s True Human™ antibodies against infectious disease targets. XBiotech owns the 48-acre campus—and all structures on the property—debt-free and envisions further expansion of facilities on the property.

Item 2 of the 10-K filed Mar 13, 2026.3

Leadership

Who has led XBiotech Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Simard2015–now

Chair

  1. John Simard2015

President

  1. John Simard2015
20202025
Board members and other officers (21)

Timeline

  1. Dec 9, 20258-K Executive or director change34
  2. Oct 15, 20258-K Executive or director change35
  3. Oct 3, 20258-K Entered a material agreement; Executive or director change36
  4. Sep 2, 20258-K Shareholder vote37
  5. Jun 24, 20258-K Executive or director change38
  6. Apr 7, 20258-K Listing notice or transfer39
  7. Apr 1, 20258-K Executive or director change40
  8. Dec 31, 20248-K Executive or director change41
  9. Jun 20, 20248-K Shareholder vote42
  10. Jan 4, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares43
  11. Jun 23, 20238-K Shareholder vote44
  12. Feb 15, 20238-K Executive or director change45
  13. Apr 14, 2015New chief executive John Simard becomes CEO12

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202646

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

101 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 15 major events, 32 insider forms, 15 large holders, 15 other. The latest 20:

  1. Oct 2, 2026ARS EDGAR
  2. Oct 2, 2026DEF 14A EDGAR
  3. Aug 13, 202610-Q EDGAR
  4. May 14, 202610-Q EDGAR
  5. Apr 29, 202610-K/A EDGAR
  6. Mar 13, 202610-K EDGAR
  7. Mar 11, 2026S-8 EDGAR
  8. Jan 23, 2026SCHEDULE 13G/A EDGAR
  9. Jan 23, 2026SCHEDULE 13G/A EDGAR
  10. Dec 9, 20258-K EDGAR
  11. Nov 12, 20254 EDGAR
  12. Nov 12, 20254 EDGAR
  13. Nov 12, 20254 EDGAR
  14. Nov 12, 20254 EDGAR
  15. Nov 12, 202510-Q EDGAR
  16. Oct 15, 20258-K/A EDGAR
  17. Oct 3, 20258-K EDGAR
  18. Sep 30, 20253 EDGAR
  19. Sep 30, 20253 EDGAR
  20. Sep 29, 20253 EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 0 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 18, 2021SIMARD JOHNChief Executive OfficerSale33,000$13.07$431.3KForm 4
Oct 15, 2021SIMARD JOHNChief Executive OfficerSale17,000$13.32$226.4KForm 4
Oct 14, 2021SIMARD JOHNChief Executive OfficerSale21,125$12.90$272.5KForm 4
Oct 13, 2021SIMARD JOHNChief Executive OfficerSale10,875$12.83$139.5KForm 4
Oct 12, 2021SIMARD JOHNChief Executive OfficerSale18,000$12.77$229.9KForm 4
Oct 7, 2021SIMARD JOHNChief Executive OfficerSale39,286$12.45$489.1KForm 4
Oct 6, 2021SIMARD JOHNChief Executive OfficerSale10,714$12.53$134.2KForm 4
Oct 5, 2021SIMARD JOHNChief Executive OfficerSale14,218$12.66$180.0KForm 4
Oct 4, 2021SIMARD JOHNChief Executive OfficerSale23,681$13.08$309.7KForm 4
Oct 1, 2021SIMARD JOHNChief Executive OfficerSale19,684$13.23$260.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025John SimardFormer President & Chief Executive Officer64$1.2M$30.1M51
2025Sushma ShivaswamyPh.D. Interim Chief Executive Officer & Chief Scientific Officer$468.6K$571.0K51
2025Angela HuDirector of Finance43$200.0K$245.4K51
2024John SimardFormer President & Chief Executive Officer64$1.2M$6.2M51
2024Sushma ShivaswamyPh.D. Interim Chief Executive Officer & Chief Scientific Officer$450.0K$657.6K51
2024Angela HuDirector of Finance43$200.0K$285.4K51

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.321,146$738.6K0.0%+28,042
Geode Capital Management, LLC214,116$492.8K0.0%−16,904
Vanguard Capital Management LLC200,182$460.4K0.0%−789
RBF Capital, LLC198,501$456.6K0.0%No change
Morgan Stanley147,880$340.1K0.0%−17,674
Bridgeway Capital Management, LLC98,447$226.4K0.0%No change
Vanguard Fiduciary Trust Co92,365$212.4K0.0%+789
Millennium Management LLC79,330$182.5K0.0%−26,210
State Street Corp73,006$167.9K0.0%No change
Northern Trust Corp66,258$152.4K0.0%−9,829
Empowered Funds, LLC59,547$137.0K0.0%No change
Renaissance Technologies LLC41,663$95.8K0.0%+19,225
Bank of New York Mellon Corp39,355$90.5K0.0%No change
Dimensional Fund Advisors LP36,053$83.0K0.0%No change
Squarepoint Ops LLC34,757$79.9K0.0%−6,457
Qube Research & Technologies Ltd33,570$77.2K0.0%+14,879
Citadel Advisors LLC29,192$67.1K0.0%New
Connor, Clark & Lunn Investment Management Ltd.27,943$64.3K0.0%−720
Bnp Paribas Financial Markets26,464$60.9K0.0%−700
National Bank Of Canada /fi/25,000$57.5K0.0%No change
Bank Of America Corp /de/23,789$54.7K0.0%−12,900
American Century Companies Inc18,381$42.3K0.0%−500
Thomasville National Bank13,350$30.7K0.0%New
XTX Topco Ltd13,080$30.1K0.0%−4,821
Pinnacle Financial Partners, Inc.11,796$27.1K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How XBiotech Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARXBiotech Inc.1
  • CIK0001626878
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inBritish Columbia3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5217 Winnebago Lane, Austin, TX 787441
  • Phone512-386-29001
  • Shares outstanding30,487,731 as of Aug 13, 202610
  • Public float$77.1M as of Jun 30, 20253
  • AuditorWhitley Penn LLP, Austin, Texas PCAOB ID 726; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 10, 20141
  • Filings403 in all: 4 (127), 8-K (58), 10-Q (35), 3 (26), SC 13G/A (22), 4/A (16), SC 13G (14), 10-K (11)1
    All 33 form types

    DEF 14A (11), CORRESP (10), DEFA14A (9), 10-K/A (8), UPLOAD (8), 424B5 (5), SC TO-I/A (5), 10-Q/A (4), ARS (4), SCHEDULE 13G/A (4), 3/A (3), 8-K/A (3), S-1/A (3), S-8 (3), EFFECT (2), FWP (2), SC TO-I (2), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), S-1 (1), S-3 (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 13, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Oct 2, 2026
    Latest 8-K (8-K) Dec 9, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, no par valueXBITNASDAQ

From the cover page of the 10-K filed Mar 13, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks XBiotech Inc. names in Item 1A of its 10-K filed Mar 13, 2026: 39 risks under these headings, as written.3

  • Risks Related to our Business, Financial Condition and Capital Requirements
  • Risks Related to Intellectual Property
  • Risks Related to Owning Shares of our Common Stock
  • General Risk Factors
  • We have incurred significant losses since our inception and may incur significant losses in the future.
  • We currently have no source of product revenue and may never sustain profitability.
  • Our future success is dependent on the regulatory approval and commercialization of our product candidates.
  • New laws or regulations may be promulgated or modified in the United States, in Europe, or other jurisdictions that could impact our ability to receive the necessary approvals to successfully market and commercialize our product candidates.
  • Because the results of earlier clinical trials are not necessarily predictive of future results, product candidates we advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval.
  • If we are unable to enroll subjects in clinical trials, we will be unable to complete these trials on a timely basis.
  • The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may fail.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval.
The other 31 risks
  • Even if our product candidates receive regulatory approval, they may still face future challenges, including ongoing regulatory oversight and marketing challenges.
  • Failure to obtain regulatory approval in foreign jurisdictions would prevent our product candidates from being marketed in those jurisdictions.
  • Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payers, which could harm our business.
  • We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements, we may be unable to generate any revenue.
  • Our product candidates, if approved, may not achieve adequate market acceptance among physicians, patients, and healthcare payers and others in the medical community necessary for commercial success.
  • Our research programs may not succeed.
  • Even an effective drug candidate might not be commercially successful.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • Our failure to successfully identify, acquire, develop and commercialize additional product candidates or approved products could impair our ability to grow.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • We will need to expand our operations and grow the size of our organization in the future, and we may experience difficulties in managing this growth.
  • We may never achieve any of the potential milestone payments that were negotiated as a part of the Janssen Transaction.
  • We depend on key personnel to operate our business. If we are unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Business disruptions caused by natural disasters, infrastructure interruptions or other public health threats could seriously harm our future revenues and financial condition and increase our costs and expenses.
  • Policy and trade decisions by government entities, including the potential use and effects of tariffs, could materially impact the macroeconomic framework in which we operate.
  • If we are unable to obtain or protect intellectual property rights, our competitive position could be harmed.
  • Intellectual property rights do not necessarily address all potential threats to any competitive advantage we may have.
  • Our technology may be found to infringe upon third-party intellectual property rights.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Risks Related to Owning Shares of Our Common Stock
  • Our share price may be volatile, which could subject us to securities class action lawsuits and prevent you from being able to sell your shares at or above the price at which you purchased them.
  • Our directors, executive officers and principal shareholders continue to have substantial control over our company and could delay or prevent a change in corporate control.
  • We have broad discretion in the use of the net proceeds from the Janssen Transaction and may not use them effectively.
  • Provisions in our charter documents under Canadian law could make an acquisition of us, which may be beneficial to our shareholders, more difficult.
  • We may be a passive foreign investment company for US tax purposes which may negatively affect US investors.
  • We are governed by the corporate laws in British Columbia, Canada which in some cases have a different effect on shareholders than the corporate laws in Delaware, United States.
  • Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Future sales, or the possibility of future sales, of a substantial number of our common stock could adversely affect the price of the shares and dilute shareholders.
  • We may have a limited ability to use some or all of our net operating loss and research tax credit carryforwards in the future.
  • If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.

Legal proceedings

The Company is not currently subject to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51